Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer-Reference-Cited by-同舟云学术

Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer

Published:2020-04-14 Issue:6 Volume:11 Page:1512-1521
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Wei Xue‐Wu¹,Gao Xin²,Zhang Xu‐Chao¹^ORCID,Yang Jin‐Ji¹^ORCID,Chen Zhi‐Hong¹,Wu Yi‐Long¹,Zhou Qing¹²^ORCID

Affiliation:

1. Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology Guangzhou China

2. The Second School of Clinical Medicine, Southern Medical University Guangzhou China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13419

Reference41 articles.

1. The cancer genome

2. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)